Transcription Phenotypes of Pancreatic Cancer Are Driven by Genomic Events During Tumor Evolution

Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor tumor cellularity and extensive genomic instability. To address this, a dataset of whole genomes and transcriptomes was generated from purified epithelium of primary and metastatic tumors. Transcriptome analysis demonstrated that molecular subtypes are a product of a gene expression continuum driven by a mixture of intratumoral subpopulations, which was confirmed by single-cell analysis. Integrated whole-genome analysis uncovered that molecular subtypes are linked to specific copy number aberrations in genes such as mutant KRAS and GATA6. By mapping tumor genetic histories, tetraploidization emerged as a key mutational process behind these events. Taken together, these data support the premise that the constellation of genomic aberrations in the tumor gives rise to the molecular subtype, and that disease heterogeneity is due to ongoing genomic instability during progression.

Citing Articles

Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study.

Chun J, Lee D, Han N, Heo S, Kim H, Lee M Cancers (Basel). 2025; 17(5).

PMID: 40075743 PMC: 11899085. DOI: 10.3390/cancers17050896.

MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC.

Fiorini E, Malinova A, Schreyer D, Pasini D, Bevere M, Alessio G Nature. 2025; .

PMID: 40074906 DOI: 10.1038/s41586-025-08721-9.

Hypoxia-induced MIR31HG expression promotes partial EMT and basal-like phenotype in pancreatic ductal adenocarcinoma based on data mining and experimental analyses.

Ko C, Yang P J Transl Med. 2025; 23(1):305.

PMID: 40065368 PMC: 11895263. DOI: 10.1186/s12967-025-06292-x.

Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System.

Beaudry F, Li Z, Borgida A, Zorigtbaatar A, Wang X, Hildebrand M Curr Oncol. 2025; 32(2).

PMID: 39996880 PMC: 11854319. DOI: 10.3390/curroncol32020080.

Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes.

Leiphrakpam P, Chowdhury S, Zhang M, Bajaj V, Dhir M, Are C J Gastrointest Cancer. 2025; 56(1):71.

PMID: 39992560 DOI: 10.1007/s12029-025-01183-2.

References

Waddell N, Pajic M, Patch A, Chang D, Kassahn K, Bailey P . Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518(7540):495-501. PMC: 4523082. DOI: 10.1038/nature14169. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

Yu J, Blackford A, Dal Molin M, Wolfgang C, Goggins M . Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015; 64(11):1783-9. PMC: 4520782. DOI: 10.1136/gutjnl-2014-308653. View

Hruban R, Goggins M, Parsons J, Kern S . Progression model for pancreatic cancer. Clin Cancer Res. 2000; 6(8):2969-72. View

Jones S, Zhang X, Parsons D, Cheng-Ho Lin J, Leary R, Angenendt P . Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-6. PMC: 2848990. DOI: 10.1126/science.1164368. View

Biankin A, Waddell N, Kassahn K, Gingras M, Muthuswamy L, Johns A . Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012; 491(7424):399-405. PMC: 3530898. DOI: 10.1038/nature11547. View

Witkiewicz A, McMillan E, Balaji U, Baek G, Lin W, Mansour J . Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015; 6:6744. PMC: 4403382. DOI: 10.1038/ncomms7744. View

Makohon-Moore A, Zhang M, Reiter J, Bozic I, Allen B, Kundu D . Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017; 49(3):358-366. PMC: 5663439. DOI: 10.1038/ng.3764. View

McDonald O, Li X, Saunders T, Tryggvadottir R, Mentch S, Warmoes M . Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet. 2017; 49(3):367-376. PMC: 5695682. DOI: 10.1038/ng.3753. View

10.

Das B . Corneal ulcer and its management. J Indian Med Assoc. 1970; 54(5):196-200. View

11.

Moffitt R, Marayati R, Flate E, Volmar K, Loeza S, Hoadley K . Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015; 47(10):1168-78. PMC: 4912058. DOI: 10.1038/ng.3398. View

12.

Collisson E, Sadanandam A, Olson P, Gibb W, Truitt M, Gu S . Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011; 17(4):500-3. PMC: 3755490. DOI: 10.1038/nm.2344. View

13.

Bailey P, Chang D, Nones K, Johns A, Patch A, Gingras M . Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47-52. DOI: 10.1038/nature16965. View

14.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

15.

Puram S, Tirosh I, Parikh A, Patel A, Yizhak K, Gillespie S . Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017; 171(7):1611-1624.e24. PMC: 5878932. DOI: 10.1016/j.cell.2017.10.044. View

16.

Agren G, Ponten J, Ronquist G, Westermark B . Formation of extracellular adenosine triphosphate by normal and neoplastic human cells in culture. J Cell Physiol. 1971; 77(3):331-6. DOI: 10.1002/jcp.1040770307. View

17.

Martinelli P, Canamero M, Del Pozo N, Madriles F, Zapata A, Real F . Gata6 is required for complete acinar differentiation and maintenance of the exocrine pancreas in adult mice. Gut. 2012; 62(10):1481-8. DOI: 10.1136/gutjnl-2012-303328. View

18.

Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T . Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018; 554(7690):62-68. PMC: 6097607. DOI: 10.1038/nature25459. View

19.

Bhathal P, Brown R, Lesueur G, Russell I . Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer. 1985; 51(2):271-8. PMC: 1977023. DOI: 10.1038/bjc.1985.39. View

20.

Krasinskas A, Moser A, Saka B, Adsay N, Chiosea S . KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Mod Pathol. 2013; 26(10):1346-54. PMC: 4128625. DOI: 10.1038/modpathol.2013.71. View